Qualigen Therapeutics Inc Cash Flow Conversion Efficiency
Qualigen Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Qualigen Therapeutics Inc (QLGN) has a cash flow conversion efficiency ratio of -0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.14 Million) by net assets ($38.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Qualigen Therapeutics Inc (2012–2024)
Cash flow conversion efficiency of Qualigen Therapeutics Inc from 2012 to 2024. This chart illustrates how Qualigen Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Qualigen Therapeutics Inc stock price for real-time trading data and today's change.
Qualigen Therapeutics Inc Cash Flow Conversion Ratio Explained
Qualigen Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Qualigen Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qualigen Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is Qualigen Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Helios Energy Ltd
AU:HE8
|
-0.020x |
|
Agro Phos India Limited
NSE:AGROPHOS
|
0.112x |
|
Sentage Holdings Inc
NASDAQ:SNTG
|
-0.060x |
|
REGENCY SILVER CORP.
F:ZJ9
|
N/A |
|
TESGAS S.A.
WAR:TSG
|
-0.092x |
|
G Capital Public Company Limited
BK:GCAP
|
-0.071x |
|
HLT Global Bhd
KLSE:0188
|
-0.159x |
|
Wyncoast Industrial Park Public Company Limited
BK:WIN
|
0.015x |
Annual Cash Flow Conversion Efficiency for Qualigen Therapeutics Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Qualigen Therapeutics Inc from 2012 to 2024. Review Qualigen Therapeutics Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.68 Million | $-6.33 Million | -2.362x | -148.22% |
| 2023-12-31 | $-2.10 Million | $-10.30 Million | 4.898x | +424.16% |
| 2022-12-31 | $8.77 Million | $-13.25 Million | -1.511x | -69.93% |
| 2021-12-31 | $16.56 Million | $-14.73 Million | -0.889x | -66.77% |
| 2020-12-31 | $18.29 Million | $-9.76 Million | -0.533x | -1123.08% |
| 2019-12-31 | $1.10 Million | $57.33K | 0.052x | +103.67% |
| 2018-12-31 | $9.39 Million | $-13.33 Million | -1.420x | -286.43% |
| 2017-12-31 | $20.13 Million | $-7.40 Million | -0.368x | +90.08% |
| 2016-12-31 | $4.10 Million | $-15.21 Million | -3.707x | -851.36% |
| 2015-12-31 | $14.68 Million | $-5.72 Million | -0.390x | +42.48% |
| 2014-12-31 | $1.71 Million | $-1.16 Million | -0.677x | -112.12% |
| 2013-12-31 | $-350.25K | $-1.96 Million | 5.587x | +271.69% |
| 2012-12-31 | $946.03K | $-3.08 Million | -3.254x | -- |
About Qualigen Therapeutics Inc
Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS tha… Read more